No Prescription |
 |
 | ||
|
NOVONORM Prandin |
|
| ||
No Prescription » Prescription Drugs 12 » NOVONORM Prandin Repaglinide is used to treat type 2 diabetes (condition in which the body does not use insulin normally and therefore cannot control the amount of sugar in the blood). Repaglinide helps your body regulate the amount of glucose (sugar) in your blood. It decreases the amount of glucose by stimulating the pancreas to release insulin.Repaglinide comes as a tablet to take by mouth. The tablets are taken before meals any time from 30 minutes before a meal to just before the meal. If you skip a meal you need to skip the dose of repaglinide. If you add an extra meal you need to take an extra dose of repaglinide. Your doctor may gradually increase your dose depending on your response to repaglinide. Follow the directions on your prescription label carefully and ask your doctor or pharmacist to explain any part you do not understand. Take repaglinide exactly as directed. Do not take more or less of it or take it more often than directed by the package label or prescribed by your doctor. Buy NOVONORM Prandin and other Prescription Drugs 12 products online at Medstore. Buy Online at Medstore - Click Here!
About NOVONORM Prandin: Product Type: Prescription Drugs 12 NOVONORM ( Prandin Generic Repaglinide ) NOVONORM (Prandin Generic Repaglinide) Prandin Generic Repaglinide 0.5mg Tabs Prandin Generic Repaglinide NOVONORM
View more Prescription Drugs 12 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
